US Stock MarketDetailed Quotes
ATHA Athira
- 0.606
- +0.178+41.53%
Close Nov 1 16:00 ET
- 0.590
- -0.016-2.57%
Post 20:01 ET
23.29MMarket Cap-204P/E (TTM)
0.747High0.544Low239.63MVolume0.589Open0.428Pre Close147.52MTurnover886.45%Turnover RatioLossP/E (Static)38.44MShares4.29852wk High0.28P/B16.38MFloat Cap0.41252wk Low--Dividend TTM27.03MShs Float34.790Historical High--Div YieldTTM47.40%Amplitude0.412Historical Low0.615Avg Price1Lot Size
About Athira Company
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
Company Profile
SymbolATHA
Company NameAthira
Listing DateSep 18, 2020
Issue Price17.00
Founded2011
CEODr. Mark J. Litton, PhD
MarketNASDAQ
Employees67
Fiscal Year Ends12-31
Address18706 North Creek Parkway,Suite 104
CityBothell
ProvinceWashington
CountryUnited States of America
Zip Code98011
Phone1-425-620-8501
Websitehttp://www.athira.com
Company Executives
- Name
- Position
- Salary
- Dr. Mark J. Litton, PhD
- Director, President and Chief Executive Officer
- 2.26M
- Dr. Kevin Church, PhD
- Chief Scientific Officer
- --
- Robert Renninger
- Principal Financial Officer, Principal Accounting Officer and Vice President, Finance
- --
- Barbara Kosacz, J.D.
- Independent Director
- 102.39K
- Grant E. Pickering
- Independent Director
- 96.53K
- Dr. Michael A. Panzara, M.D.
- Independent Director
- 89.36K
- Joseph Edelman
- Independent Director
- 92.77K
- John M. Fluke, Jr
- Independent Director
- 95.89K
- James A. Johnson
- Independent Director
- 106.87K
- Mark Worthington
- General Counsel and Corporate Secretary
- --
- Kelly A. Romano
- Chairwoman of the Board
- 124.68K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
